Matrifen (Fentanyl)

Matrifen contains fentanyl, an opioid that acts on the central nervous system to control persistent severe pain.

• Severe chronic pain: delivers continuous opioid analgesia for patients with long‑term, high‑intensity pain.
• Cancer pain: manages moderate to severe pain associated with malignant disease, improving quality of life.
• End‑of‑life care: offers sustained pain control for patients receiving palliative or hospice care.

• Fentanyl is a potent agonist at mu‑opioid receptors in the central nervous system. By binding to these G‑protein‑coupled receptors, it inhibits the release of excitatory neurotransmitters, reduces neuronal excitability, and diminishes the perception of pain, producing strong analgesic effects.

Fentanyl transdermal therapy may be associated with a range of adverse reactions.

Common Side Effects

• Nausea and vomiting
• Constipation
• Dizziness or light‑headedness
• Somnolence or fatigue
• Dry mouth
• Sweating

Serious or Rare Side Effects

• Respiratory depression, potentially life‑threatening
• Severe hypotension or cardiovascular collapse
• Opioid dependence or withdrawal syndrome
• Severe skin reactions at the patch site
• Anaphylaxis or severe hypersensitivity
• Adrenal insufficiency with prolonged use

When prescribing or using Matrifen, clinicians and patients should observe several safety measures.

• Assess opioid tolerance: confirm the patient is opioid‑tolerant before initiating therapy.
• Monitor respiratory function: watch for signs of respiratory depression, especially during dose adjustments.
• Avoid use in severe respiratory compromise: contraindicated in patients with uncontrolled asthma or COPD exacerbations.
• Use with caution in hepatic impairment: reduced metabolism may increase fentanyl exposure.
• Store at room temperature: keep patches in the original packaging, protect from moisture and direct sunlight.

Fentanyl may interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid)

• Central nervous system depressants (e.g., benzodiazepines, barbiturates): risk of profound sedation and respiratory depression.
• Monoamine oxidase inhibitors (MAOIs): can precipitate severe hypotension or serotonin syndrome.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase fentanyl plasma levels, heightening toxicity.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce analgesic effect.
• Serotonergic agents (e.g., SSRIs, tramadol): monitor for serotonin syndrome.
• Alcohol: additive CNS depression, requires careful observation.
• Other opioids: cumulative opioid effect may necessitate dose adjustments.